Clinical Trials Logo

Clinical Trial Summary

A Multi-center, Open-label Phase II Clinical Trial of TJ271 Injection in Combination with Pembrolizumab in Chinese Patients with Advanced Solid Tumors to evaluate the anti-tumor efficacy, safety, pharmacokinetics and immunogenicity of TJ271 in combination with pembrolizumab in patients with advanced solid tumors.


Clinical Trial Description

A Multi-center, Open-label Phase II Clinical Trial of TJ271 Injection in Combination with Pembrolizumab in Chinese Patients with Advanced Solid Tumors to evaluate the anti-tumor efficacy, safety, pharmacokinetics and immunogenicity of TJ271 in combination with pembrolizumab in patients with advanced solid tumors. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05338580
Study type Interventional
Source TJ Biopharma Co., Ltd.
Contact
Status Withdrawn
Phase Phase 2
Start date December 31, 2023
Completion date December 31, 2023